RESUMEN
INTRODUCTION: Acute gout occurs in people with chronic kidney disease, who are commonly older people with comorbidities such as hypertension, heart disease and diabetes. Potentially harmful treatments are administered to these vulnerable patients due to a lack of clear evidence. Newly available treatment that targets a key inflammatory pathway in acute gout attacks provides an opportunity to undertake the first-ever trial specifically looking treating people with kidney disease. This paper describes the protocol for a feasibility randomised controlled trial (RCT) comparing anakinra, a novel interleukin-1 antagonist versus steroids in people with chronic kidney disease (ASGARD). METHODS AND ANALYSIS: ASGARD is a two-parallel group double-blind, double-dummy multicentre RCT comparing anakinra 100 mg, an interleukin-1 antagonist, subcutaneous for 5 days against intramuscular methylprednisolone 120 mg. The primary objective is to assess the feasibility of the trial design and procedures for a definitive RCT. The specific aims are: (1) test recruitment and retention rates and willingness to be randomised; (2) test eligibility criteria; (3) collect and analyse outcome data to inform sample and power calculations for a trial of efficacy; (4) collect economic data to inform a future economic evaluation estimating costs of treatment and (5) assess capacity of the project to scale up to a national multicentre trial. We will also gather qualitative insights from participants. It aims to recruit 32 patients with a 1:1 randomisation. Information from this feasibility study will help design a definitive trial and provide general information in designing acute gout studies. ETHICS AND DISSEMINATION: The London-Central Ethics Committee approved the protocol. The results will be disseminated in peer-reviewed journals and at scientific conferences. TRIAL REGISTRATION NUMBER: EudraCT No. 2015-001787-19, NCT/Clinicalstrials.gov No. NCT02578394, pre-results, WHO Universal Trials Reference No. U1111-1175-1977. NIHR Grant PB-PG-0614-34090.
Asunto(s)
Gota/tratamiento farmacológico , Proteína Antagonista del Receptor de Interleucina 1/administración & dosificación , Metilprednisolona/administración & dosificación , Insuficiencia Renal Crónica/complicaciones , Análisis Costo-Beneficio , Método Doble Ciego , Estudios de Factibilidad , Humanos , Inyecciones Intramusculares , Calidad de Vida , Receptores de Interleucina-1/antagonistas & inhibidores , Proyectos de Investigación , Reino UnidoRESUMEN
Elizabeth Blyth worked as a small animal vet and was married to a vet.
Asunto(s)
Medicina Veterinaria/historia , Historia del Siglo XX , Historia del Siglo XXI , Reino UnidoRESUMEN
Factor H autoantibodies can impair complement regulation, resulting in atypical hemolytic uremic syndrome, predominantly in childhood. There are no trials investigating treatment, and clinical practice is only informed by retrospective cohort analysis. Here we examined 175 children presenting with atypical hemolytic uremic syndrome in the United Kingdom and Ireland for factor H autoantibodies that included 17 children with titers above the international standard. Of the 17, seven had a concomitant rare genetic variant in a gene encoding a complement pathway component or regulator. Two children received supportive treatment; both developed established renal failure. Plasma exchange was associated with a poor rate of renal recovery in seven of 11 treated. Six patients treated with eculizumab recovered renal function. Contrary to global practice, immunosuppressive therapy to prevent relapse in plasma exchange-treated patients was not adopted due to concerns over treatment-associated complications. Without immunosuppression, the relapse rate was high (five of seven). However, reintroduction of treatment resulted in recovery of renal function. All patients treated with eculizumab achieved sustained remission. Five patients received renal transplants without specific factor H autoantibody-targeted treatment with recurrence in one who also had a functionally significant CFI mutation. Thus, our current practice is to initiate eculizumab therapy for treatment of factor H autoantibody-mediated atypical hemolytic uremic syndrome rather than plasma exchange with or without immunosuppression. Based on this retrospective analysis we see no suggestion of inferior treatment, albeit the strength of our conclusions is limited by the small sample size.
Asunto(s)
Síndrome Hemolítico Urémico Atípico/inmunología , Autoanticuerpos/sangre , Fallo Renal Crónico/inmunología , Trasplante de Riñón , Adolescente , Anticuerpos Monoclonales Humanizados/uso terapéutico , Síndrome Hemolítico Urémico Atípico/sangre , Síndrome Hemolítico Urémico Atípico/genética , Síndrome Hemolítico Urémico Atípico/terapia , Niño , Preescolar , Factor H de Complemento/inmunología , Proteínas del Sistema Complemento/análisis , Proteínas del Sistema Complemento/genética , Femenino , Humanos , Terapia de Inmunosupresión/efectos adversos , Terapia de Inmunosupresión/métodos , Lactante , Irlanda , Fallo Renal Crónico/sangre , Fallo Renal Crónico/genética , Fallo Renal Crónico/terapia , Masculino , Intercambio Plasmático , Recurrencia , Diálisis Renal , Estudios Retrospectivos , Reino UnidoRESUMEN
BACKGROUND: Sphingobacterium spiritivorum is a microorganism that is ubiquitously found in the environment. However, it is rarely isolated from human clinical specimens. There are few reports to date of Sphingobacterium spiritivorum causing disease in humans. CASE REPORT: We describe a case of Sphingobacterium spiritivorum infection in a patient on haemodialysis, which to our knowledge, has not been described before. Further testing revealed this strain was sensitive to multiple antimicrobials. CONCLUSION: Despite interrupted courses of several antibiotics, our patient clinically made a good recovery and continued to receive haemodialysis.
Asunto(s)
Infecciones por Bacterias Gramnegativas/microbiología , Fallo Renal Crónico/microbiología , Sphingobacterium/aislamiento & purificación , Anciano de 80 o más Años , Antibacterianos/farmacología , Femenino , Infecciones por Bacterias Gramnegativas/terapia , Humanos , Fallo Renal Crónico/terapia , Filogenia , Diálisis Renal , Sphingobacterium/clasificación , Sphingobacterium/efectos de los fármacos , Sphingobacterium/genéticaRESUMEN
OBJECTIVE: Haemodialysis patients are at risk of serious health complications; yet, treatment non-adherence remains high. Warnings about health risks associated with non-adherence may trigger defensive reactions. We studied whether an intervention based on self-affirmation theory reduced resistance to health-risk information and improved fluid treatment adherence. DESIGN: In a cluster randomised controlled trial, 91 patients either self-affirmed or completed a matched control task before reading about the health-risks associated with inadequate fluid control. OUTCOME MEASURES: Patients' perceptions of the health-risk information, intention and self-efficacy to control fluid were assessed immediately after presentation of health-risk information. Interdialytic weight gain (IDWG), excess fluid removed during haemodialysis, is a clinical measure of fluid treatment adherence. IDWG data were collected up to 12 months post-intervention. RESULTS: Self-affirmed patients had significantly reduced IDWG levels over 12 months. However, contrary to predictions derived from self-affirmation theory, self-affirmed participants and controls did not differ in their evaluation of the health-risk information, intention to control fluid or self-efficacy. CONCLUSION: A low-cost, high-reach health intervention based on self-affirmation theory was shown to reduce IDWG over a 12-month period, but the mechanism by which this apparent behaviour change occurred is uncertain. Further work is still required to identify mediators of the observed effects.
Asunto(s)
Fluidoterapia/psicología , Promoción de la Salud/métodos , Cooperación del Paciente/psicología , Diálisis Renal , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Intención , Masculino , Persona de Mediana Edad , Teoría Psicológica , Autoeficacia , Resultado del Tratamiento , Aumento de PesoRESUMEN
OBJECTIVES: Patients with end-stage kidney disease receiving haemodialysis (HD) are at risk of cardiovascular disease and bone disorders related to high levels of serum phosphate. We studied the association between medication beliefs and depressive symptoms, with non-adherence to phosphate binding medication in a group of HD patients at risk of complications due to hyperphosphatemia. DESIGN: Cross-sectional design. METHODS: Baseline data from 112 patients participating in a randomized controlled trial, evaluating an adherence intervention, are presented. All patients had serum phosphate levels >1.6 mmol/l at baseline. Adherence was measured by (1) serum phosphate and (2) Medication Adherence Report Scales (MARS). Beliefs about Medicines (BMQ) and depressive symptoms (PHQ-9) were also evaluated. RESULTS: Beliefs about Medicines Questionnaire necessity, but not concerns, beliefs were found to correlate with serum phosphate (r = -.23, p < .05) and self-reported adherence (r = .35, p < .01). In regression models, controlling for demographic, clinical and psychological variables, necessity beliefs explained the variance of serum phosphate (ß = -.22, p = .01) and self-reported adherence (ß = .30, p ≤ .01). Both BMQ concerns and depressive symptoms were not related to non-adherence. CONCLUSION: Patients' beliefs about the necessity of their prescribed phosphate binding medications explain variation in non-adherence levels, measured both subjective and objectively. Dialysis patient's medication beliefs are potentially modifiable targets for future interventions.
Asunto(s)
Actitud Frente a la Salud , Quelantes/uso terapéutico , Depresión/psicología , Hiperfosfatemia/tratamiento farmacológico , Fallo Renal Crónico/terapia , Cumplimiento de la Medicación/psicología , Diálisis Renal , Adulto , Anciano , Estudios Transversales , Femenino , Humanos , Hiperfosfatemia/psicología , Masculino , Persona de Mediana Edad , Encuestas y CuestionariosRESUMEN
Rapidly developing renal milk of calcium, diagnosed by computed tomography (CT), X-ray and ultrasound, should be considered as a rare differential diagnosis in patients with apparent ureteric obstruction to prevent unnecessary interventions.
RESUMEN
OBJECTIVE: We sought to examine several competing factor structures of the Beck Depression Inventory-II (BDI) in a sample of patients with End-Stage Renal Disease (ESRD), in which setting the factor structure is poorly defined, though depression symptoms are common. In addition, demographic and clinical correlates of the identified factors were examined. METHODS: The BDI was administered to clinical sample of 460 ESRD patients attending 4 UK renal centres. Competing models of the factor structure of the BDI were evaluated using confirmatory factor analysis. RESULTS: The best fitting model consisted of general depression factor that accounted for 81% of the common variance between all items along with orthogonal cognitive and somatic factors (G-S-C model, CFI=.983, TLI=.979, RMSEA=.037), which explained 8% and 9% of the common variance, respectively. Age, diabetes, and ethnicity were significantly related to the cognitive factor, whereas albumin, dialysis adequacy, and ethnicity were related to the somatic factor. No demographic or clinical variable was associated with the general factor. CONCLUSION: The general-factor model provides the best fitting and conceptually most acceptable interpretation of the BDI. Furthermore, the cognitive and somatic factors appear to be related to specific demographic and clinical factors.
Asunto(s)
Depresión/diagnóstico , Depresión/psicología , Fallo Renal Crónico/psicología , Inventario de Personalidad/normas , Diálisis Renal/psicología , Anciano , Cognición , Análisis Factorial , Femenino , Humanos , Fallo Renal Crónico/terapia , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Índice de Severidad de la EnfermedadAsunto(s)
Eritropoyetina/administración & dosificación , Eritropoyetina/efectos adversos , Aplasia Pura de Células Rojas/inducido químicamente , Anciano , Anciano de 80 o más Años , Anemia/tratamiento farmacológico , Ciclosporina/uso terapéutico , Epoetina alfa , Hematínicos/administración & dosificación , Hematínicos/efectos adversos , Humanos , Inmunosupresores/uso terapéutico , Fallo Renal Crónico/tratamiento farmacológico , Masculino , Proteínas RecombinantesAsunto(s)
Eritropoyetina/análogos & derivados , Eritropoyetina/administración & dosificación , Eritropoyetina/efectos adversos , Aplasia Pura de Células Rojas/inducido químicamente , Diálisis Renal , Anciano , Anciano de 80 o más Años , Anticuerpos/inmunología , Ciclosporina/uso terapéutico , Darbepoetina alfa , Resistencia a Medicamentos , Epoetina alfa , Eritropoyetina/inmunología , Eritropoyetina/uso terapéutico , Humanos , Inmunosupresores/uso terapéutico , Masculino , Proteínas Recombinantes , Aplasia Pura de Células Rojas/inmunología , Recuento de Reticulocitos , RetratamientoRESUMEN
BACKGROUND: Renal involvement is frequently present in antineutrophil cytoplasmic autoantibody (ANCA)-associated systemic vasculitis and is an important cause of end-stage renal failure (ESRF). METHODS: This retrospective, multicenter, sequential cohort study reports presenting features and outcome of 246 new patients diagnosed in London, UK, between 1995 and 2000. RESULTS: Diagnostic subgroups were microscopic polyangiitis, 120 patients (49%); Wegener's granulomatosis (WG), 82 patients (33%); renal-limited vasculitis, 33 patients (13.5%); and Churg-Strauss angiitis, 11 patients (4.5%). Median age was 66 years, 57% were men, and median creatinine level at presentation was 3.87 mg/dL (342 micromol/L). ANCA was present in 92%. Cumulative patient survival at 1 and 5 years was 82% and 76%, respectively. Mortality was associated with age older than 60 years (P < 0.001), development of ESRF (P < 0.001), initial creatinine level greater than 2.26 mg/dL (200 micromol/L; P = 0.01), and sepsis (P < 0.048). ESRF occurred in 68 patients (28%), of whom 47% died. Fifty-six patients who presented with a creatinine level greater than 5.65 mg/dL (500 micromol/L) survived, and 31 patients (55%) achieved dialysis independence. Relapse occurred in 34% after a median of 13 months and was more common in patients with WG (P = 0.048) and proteinase 3-ANCA (P = 0.034). Leukopenia occurred in 41% and was associated with sepsis (P < 0.001). CONCLUSION: Mortality and morbidity of ANCA-associated systemic vasculitis are improving compared with previous series, but remain high. Renal vasculitis often affects older patients, who have a particularly poor outcome. Early diagnosis improves outcome. Leukopenia, caused by immunosuppressive therapy, should be avoided because of the close association with sepsis and death.